News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Hsin‑Nung Shih, MD

Articles by Hsin‑Nung Shih, MD

Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study

ByShiny Chih-Hsuan Wu, MD,Yao-Yu Wu, MD,Chi-Ting Liau, MD,Chih‑Hsiang Chang, MD,Shih-Chiang Huang, MD,Hsin‑Nung Shih, MD,Chun-Chieh Chen, MD, PhD

March 26th 2026

Latest Updated Articles

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study
March 26th 2026

Trending on CancerNetwork

Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial

Cellular Therapy and Antibody-Drug Conjugates Shape Day 1 of ASCO Breakthrough 2026

Offering Hope and Support Toward the Cancer Survivorship Journey

AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026

GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations